현재 위치
Home
Session V: Industry Level Development and Production of Recombinant Glycoprotein Therapeutics, Chair : Dr. Hyun Ah Kang (Chung-Ang Univ., Korea)
Process scale up and cGMP manufacturing of recombinant therapeutic glycoprotein.
-
- 발행기관
- 한국당과학회 바로가기
-
- 간행물
- 한국당과학회 학술대회 바로가기
-
- 통권
- 2008 Eastern Asian Glycoscience Symposium (2008.11)바로가기
-
- 페이지
- pp.34-34
-
- 저자
-
- 언어
- 영어(ENG)
-
- URL
- https://www.earticle.net/Article/A192305
※ 원문제공기관과의 협약기간이 종료되어 열람이 제한될 수 있습니다.
원문정보
초록
- 영어
- Biopharmaceuticals are medical drugs produced using biotechnology. They are proteins (including antibodies) and nucleic acids (DNA, RNA or antisense oligonucleotides) used for therapeutic or in vivo diagnostic purposes. These so called large molecule pharmaceuticals can be produced from recombinant microbial cells, mammalian cell lines or plant cell cultures. Biopharmaceuticals are typically large molecules, requires complex post translational modification and glycosylation processes. Its glycosylation pattern affects biological activity, function, clearance from blood circulation, and most importantly it could also elicit immune response in patients. Due to that reasons, bacteria, yeasts, fungi, insects and plants are generally not suitable for the expression of therapeutic glycoproteins such as antibodies. The worldwide market for therapeutic and diagnostic monoclonal antibodies is expected to reach USD$26 billion by 2010. First Antibody for pharmaceutical was approved in 1986 and currently there are more than 23 therapeutic antibodies approved by US FDA in the market. The numbers are still growing. With hundreds of product candidates in the pipeline getting into clinical stage phase I, II and III, there is a huge demand for contract manufacturing sector as well. InnoBio operates as a contract manufacturer (CMO) and is positioning itself as one of the player for biopharmaceutical production. Established in 2003, the services include all stages of the production of mammalian cell-based therapeutic proteins and monoclonal antibodies, from DNA recombination work and bioprocess development to cGMP manufacturing. In this talk, the experience in setting up a cGMP manufacturing plant and manpower development together with support facility will be discussed.
저자
간행물 정보
발행기관
-
- 발행기관명
- 한국당과학회 [Korean Society for Glycoscience]
- 설립연도
- 2006
- 분야
- 의약학>약학
- 소개
- 본 학회는 화학, 생화학, 분자생물학, 미생물학, 식품공학, 의학, 약학, 유전공학 및 생물공학, 환경 및 기타 공업 등 전 분야의 탄수화물관련 이론과 기술을 연구 발전시키고 산학협동을 통해 이를 보급하여 국내 관련 산업의 발전 및 국민생활의 과학화에 기여하고자 하며, 이러한 목표와 비젼의 실현을 위해 회원들이 적극적인 참여와 활동을 전개하고자 한다.
간행물
-
- 간행물명
- 한국당과학회 학술대회
- 간기
- 연간
- 수록기간
- 2006~2022
- 십진분류
- KDC 517 DDC 614
이 권호 내 다른 논문 / 한국당과학회 학술대회 2008 Eastern Asian Glycoscience Symposium
피인용수 : 0건 (자료제공 : 네이버학술정보)
함께 이용한 논문 이 논문을 다운로드한 분들이 이용한 다른 논문입니다.
출처 : 네이버학술정보
0개의 논문이 장바구니에 담겼습니다.